- Sweden
- /
- Medical Equipment
- /
- OM:STIL
Stille AB Just Missed EPS By 93%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Stille AB (STO:STIL), given that the company fell short of expectations when it released its third-quarter results last week. Results showed a clear earnings miss, with kr139m revenue coming in 8.4% lower than what the analystsexpected. Statutory earnings per share (EPS) of kr0.10 missed the mark badly, arriving some 93% below what was expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the consensus forecast from Stille's two analysts is for revenues of kr652.7m in 2026. This reflects a notable 18% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 98% to kr9.20. In the lead-up to this report, the analysts had been modelling revenues of kr701.6m and earnings per share (EPS) of kr9.60 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the minor downgrade to earnings per share expectations.
See our latest analysis for Stille
It'll come as no surprise then, to learn that the analysts have cut their price target 10% to kr232.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Stille's revenue growth is expected to slow, with the forecast 14% annualised growth rate until the end of 2026 being well below the historical 30% p.a. growth over the last five years. Compare this to the 56 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 15% per year. So it's pretty clear that, while Stille's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also downgraded their revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for Stille going out as far as 2027, and you can see them free on our platform here.
It is also worth noting that we have found 1 warning sign for Stille that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:STIL
Stille
Develops, manufactures, and distributes medtech products in Sweden and internationally.
Flawless balance sheet and good value.
Similar Companies
Market Insights
Community Narratives

